Jonathan Radcliffe

Consultant

Jonathan's practice focuses on patent and IP litigation and strategy.

His practice is primarily litigious, although he also advises on strategy and the IP aspects of corporate work. His practice covers a wide range of technologies, with a particular focus on cases with a high scientific/technological content. He has led pan-European and multi-national patent litigation (including as part of joint in-house and private practice teams).

He represents clients in the life sciences, medical devices, high-tech, and manufacturing sectors (including biometrics, electronics, software, and communications).

He has extensive experience in acting for international clients on multinational matters and regularly advises on pan-European and multinational disputes, including acting as European co-ordinating counsel. He has worked in New York and in Abu Dhabi.

Jonathan has acted in a number of leading cases in the IP field on matters such as the patentability of software, added matter, preventing attempted post-revocation patent amendment, obviousness, importation as an act of infringement under the Patents Act, entitlement to patents and inventions, patent injunctions, the trade mark classification system, and the registerability of shape trade marks.

Jonathan is believed to be one of only two English solicitors to have had both a patent appeal and a separate trade mark appeal to the UK Supreme Court.

He has also acted for many years for one of the world’s leading auction houses, and so has a deep expertise in related copyright, moral rights, and artists’ resale right issues.

Experience

Representative matters

Advising Abbott Laboratories and the Europe-based inventors of Humira on certain European aspects of the primary US patent litigation on its biologic Humira, principally relating to the evidence of the invention of Humira and the attack by Centocor on the inventiveness and validity of the patents.
Advising a leading specialist antibody company on patent infringement assertions against its high affinity sheep monoclonal antibody clinical diagnostic test used for vitamin D immunoassays, and formulating strategies for offensive revocation/DNI litigation and European Patent Office opposition. This matter settled favourably on a license basis.
Advising a global life sciences company on pan-European and global defensive and offensive strategies against its principal competitors for a major new biologic, including; optimising its patent portfolio, preparing for offensive revocation/DNI litigation (and injunctions) against competitors, preparing for defensive infringement litigation, preparing European Patent Office strategies, litigation input into optimising patent filings.

Recognitions

  • Selected to the IAM Patent 1000, which identifies the top patent practitioners throughout the world, 2025-2026

  • Ranked in The World Trademark Review (WTR) 1000, 2024-2026

  • Selected through peer review for inclusion in The Best Lawyers™ in the United Kingdom for Intellectual Property Law, 2009-2025

Credentials

Education

  • University of Oxford, 1983, M.A.

Professional admissions & qualifications

  • England and Wales
  • Ireland

Professional affiliations

  • Associate of the Chartered Institute of Patent Agents (CIPA)
  • Associate of the Institute of Trade Mark Agents (ITMA)
  • Member of the International Trademark Association (INTA)
  • Member of the International Association for the Protection of Industrial Property (AIPPI)
  • Member of the United Kingdom Department of Trade & Industry official delegation to the BioMed conference 2009

News

Notable Quotes